Navigation Links
ImClone Systems Showcases Extensive Research and Development,Program at the AACR Annual Meeting

NEW YORK--(BUSINESS WIRE)--Apr 19, 2007 - IgG1 monoclonal antibodies developed by ImClone Systems Incorporated (NASDAQ: IMCL) were the focus of 44 total presentations at the recently concluded 98th Annual Meeting of the American Association for Cancer Research (AACR), including seven oral presentations and 37 posters.

Important ERBITUX(R) (cetuximab) clinical data were the focus of two back-to-back oral presentations leading off the "Breakthroughs in Clinical Research" Plenary Session on April 16, 2007, which highlights the most important clinical studies presented at this prestigious meeting. The remaining presentations showcased ImClone's extensive research and development program with results from studies involving both ERBITUX, an IgG1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR), and multiple investigational monoclonal antibodies in the ImClone pipeline that target other critical cancer pathways.

Like ERBITUX, the monoclonal antibodies in the ImClone pipeline are all type 1 immunoglobulin G (IgG1) antibodies. In vitro, IgG1 antibodies elicit antibody-dependent cellular cytotoxicity (ADCC), which can kill cancer cells and may contribute to their overall therapeutic effects. These novel fully human antibodies, many of which are in early phase clinical testing, target cell surface receptors in various signaling pathways known or believed to play important roles in the growth and proliferation of tumors or tumor vasculature. Specific targets include insulin-like growth factor-1 receptor (IGF-1R), vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor alpha (PDGFR(alpha)), FMS-like tyrosine kinase 3 receptor (FLT3), fibroblast growth factor receptor 3 (FGFR3), among others.

"Our pipeline consists of a robust collection of IgG1 monoclonal antibodies targeted against cellular pathways that are emerging as cri
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO
2. When Volume Matters, Immunoassay Systems Deliver
3. Genetic Analysis Systems Enter the Clinical Mainstream
4. New Quality Control Systems for Every Laboratory Application
5. Immunoassay Systems - Your Laboratory Workhorse
6. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
7. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
8. NIEHS Researchers Identify Enzyme Critical in DNA Replication
9. Stanford Researchers Find Brain Pathway of Depression in Rats
10. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
11. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
Post Your Comments:
(Date:1/15/2014)... January 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender offer ...   As a result of the waiver, the transaction ... complete the tender offer on January 24, 2014 following the currently ...
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... 2014 The Cadence Fitness & Health Center has ... Medical Fitness Association, a non-profit organization assisting medically integrated ... The Cadence Fitness & Health Center is the only ... in the Chicagoland area. "The certification means ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... MEDomics, LLC provides NextGen sequence-based DNA diagnostic ... era and is transforming diagnostic testing for mitochondrial ... capital investment from our partner, SpaGus Ventures LLC. ... used by MEDomics to fuel the continued growth ...
... FLORHAM PARK, N.J., April 7, 2011 Shionogi Inc., ... today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) ... reduce chronic severe drooling in patients aged 3 to ... as cerebral palsy. "Shionogi is proud ...
Cached Medicine Technology:MEDomics Announces a Growth Capital Investment from SpaGus Ventures LLC and Gary Augusta Joins MEDomics as Chief Operating Officer 2Shionogi Announces Commercial Availability of CUVPOSA™ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions 2Shionogi Announces Commercial Availability of CUVPOSA™ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions 3Shionogi Announces Commercial Availability of CUVPOSA™ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions 4Shionogi Announces Commercial Availability of CUVPOSA™ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions 5
(Date:4/24/2014)... at the University of York reveals that a process ... the nervous system may also play a pivotal role ... team, led by Dr Will Brackenbury, a Medical Research ... has studied how voltage-gated sodium channels assist in the ... the membranes of excitable cells, such as neurons, where ...
(Date:4/23/2014)... stool from healthy, unrelated donors was safe and ... caused by Clostridium difficile , according to ... Infectious Diseases and available online. Known as ... whether given via a colonoscope or a nasogastric ... this promising treatment more readily available to patients. ...
(Date:4/23/2014)... researchers say clinical trials for a new experimental ... very promising. Patients treated with CPX-351, a combination ... showing better responses than patients treated with the ... myeloid leukemia is an aggressive blood cancer with ... older patients," explained Jeffrey Lancet, M.D., senior member ...
(Date:4/23/2014)... M.D., scientific director at the National Institute of Arthritis ... the 2014 recipient of the Ross Prize in Molecular ... Molecular Medicine . The award will be given ... Sciences in Manhattan, followed by scientific presentations by Dr. ... the National Institutes of Health. , The award, which ...
(Date:4/23/2014)... 2014 The American Society for Radiation Oncology (ASTRO) ... Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO ... radiation therapy in the treatment of endometrial cancer. ... May-June 2014 issue of Practical Radiation Oncology ... ASTRO. The full-length guideline is available as an ...
Breaking Medicine News(10 mins):Health News:Breast cancer replicates brain development process 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
... To reduce mortality and improve patient care in the ... Care Societies Collaborative (CCSC), in conjunction with the US ... that research in the field become less fragmented and ... critical illness. The CCSC comprises the ...
... a popular activity in nursing homes, senior centers ... beyond socializing. Researchers found high-contrast, large bingo cards ... cognitive difficulties and visual perception problems produced by ... "The general finding of improved performance across healthy ...
... Michigan State University researchers one working at a medieval ... in East Lansing have shown how modern science can ... the first to confirm the existence of brucellosis, an infectious ... The findings, which appear in the American Journal of ...
... best cigarette is no cigarette, but for the millions ... researchers from Cornell University may have found a way ... antioxidant extracts in cigarette filters, the researchers were able ... reduced the amount of cancer-causing free radicals passing through ...
... suggests that there may be a positive relationship between ... to a report in the January issue of ... the JAMA/Archives journals. Amika Singh, Ph.D., of the ... and Care Research, Amsterdam, the Netherlands, and colleagues reviewed ...
... , SUNDAY, Jan. 1 (HealthDay News) -- Losing weight is ... long-held behaviors is a skill in itself, a medical expert ... people have to be ready to face some setbacks and ... and medical weight-loss specialist at Gottlieb Memorial Hospital, part of ...
Cached Medicine News:Health News:ATS issues joint statement on key issues and recommendations for critical care research 2Health News:ATS issues joint statement on key issues and recommendations for critical care research 3Health News:'BINGO!' game helps researchers study perception deficits 2Health News:Scientists crack medieval bone code 2Health News:Physical activity, school performance may be linked 2Health News:Persistence Is Key to Losing Weight and Keeping It Off 2Health News:Persistence Is Key to Losing Weight and Keeping It Off 3
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... is a flexible system that ... environments small hospitals, backup ... satellite locations. The Vitros 250 ... can be automated or placed ...
... an effort to improve on the ... toxicology, abused drugs, and immunosuppressants tests, ... which incorporates random access capabilities. Although ... undergone several important changes in the ...
The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
Medicine Products: